| Name | Title | Contact Details |
|---|
Shore Medical Center operates as a hospital facility. It offers anesthesiology, balance, blood bank, cancer, cardiovascular, critical, diabetes education, endoscopy, hospitalist, kidney disease, laboratory, maternal-fetal medicine, neurosciences, nutrition, outpatient testing, palliative, pulmonary diagnostic, radiology and diagnostic imaging, rehabilitation, respiratory, sleep medicine, social, spine and orthopedic, stroke, surgical, urgent, wound and hyperbaric medicine, vascular, neurological, emergency, and maternity and pediatric health care services. Shore Medical Center was formerly known as Shore Medical Center. The company is based in Somers Point, New Jersey. Shore Medical Center operates as a subsidiary of Shore Health Systems Inc.
Hudson Valley Senior Residence is a Kingston, NY-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Orlando Senior Health Network is a network of companies that provides a broad range of residential living options, home care and rehabilitation services, plus pharmaceutical and medical equipment offerings, designed to improve the quality of life for s...
Bach Mobilities Inc is a Escanaba, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
ContraVir is a biopharmaceutical company focused primarily on the development of drugs to treat herpes zoster, or shingles, which is an infection caused by the reactivation of varicella zoster virus or VZV. Our lead candidate, FV-100, is an orally available nucleoside analogue prodrug of CF-1743 that we are developing for the treatment of shingles. Published preclinical studies demonstrate that FV-100 is significantly more potent against VZV than acyclovir, valacyclovir, and famciclovir, the FDA-approved drugs used for the treatment of shingles. Preclinical studies further demonstrate that FV-100 has a more rapid onset of antiviral activity, and may fully inhibit the replication of VZV more rapidly than these drugs at significantly lower concentration levels. In addition, pharmacokinetic data from completed phase 1 and 2 clinical trials suggest that FV-100 has the potential to demonstrate antiviral activity when dosed orally once-a-day at significantly lower levels than valacyclovir, acyclovir, and famciclovir.